Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 2;12(12):CD003733.
doi: 10.1002/14651858.CD003733.pub5.

Inhaled bronchodilators for acute chest syndrome in people with sickle cell disease

Jennifer M Knight-Madden  1 , Ian R Hambleton  2
Affiliations

Inhaled bronchodilators for acute chest syndrome in people with sickle cell disease

Jennifer M Knight-Madden et al. Cochrane Database Syst Rev. .

Abstract

Background: Bronchodilators are used to treat bronchial hyper-responsiveness in asthma. Bronchial hyper-responsiveness may be a component of acute chest syndrome in people with sickle cell disease. Therefore, bronchodilators may be useful in the treatment of acute chest syndrome. This is an update of a previously published Cochrane Review.

Objectives: The aim of the review is to determine whether the use of inhaled, short-acting bronchodilators for acute chest syndrome reduces morbidity and mortality in people with sickle cell disease and to assess whether this treatment causes adverse effects.

Search methods: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Trials Register comprising references identified from comprehensive electronic database searches, handsearches of relevant journals and abstract books of conference proceedings. Additional searches were carried out on MEDLINE (1966 to 2004) and Embase (1981 to 2004) and ongoing trial registries (28 September 2022). Date of the most recent search of the Group's Haemoglobinopathies Trials Register: 25 July 2022.

Selection criteria: Randomised or quasi-randomised controlled trials. Trials using quasi-randomisation methods will be included in future updates of this review if there is sufficient evidence that the treatment and control groups are similar at baseline.

Data collection and analysis: We found no trials investigating the use of bronchodilators for acute chest syndrome in people with sickle cell disease.

Main results: We found no trials investigating the use of bronchodilators for acute chest syndrome in people with sickle cell disease.

Authors' conclusions: If bronchial hyper-responsiveness is an important component of some episodes of acute chest syndrome in people with sickle cell disease, the use of inhaled bronchodilators may be indicated. There is need for a well-designed, adequately-powered randomised controlled trial to assess the benefits and risks of the addition of inhaled bronchodilators to established therapies for acute chest syndrome in people with sickle cell disease.

PubMed Disclaimer

Conflict of interest statement

Jennifer Knight‐Madden declares no known potential conflict of interest.

Ian Hambleton declares no known potential conflict of interest.

Figures

1
1
Study flow diagram.
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

References

Additional references

Al Hajeri 2008
    1. Al Hajeri A, Serjeant GR, Fedorowicz Z. Inhaled nitric oxide for acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No: CD006957. [DOI: 10.1002/14651858.CD006957] - DOI - PMC - PubMed
Armitage 1994
    1. Armitage P, Berry G. Further analysis of categorical data. Kappa measure of agreement. In: Statistical Methods in Medical Research. 3rd edition. Oxford: Blackwell Press, 1994:443-5.
Barnes 2000
    1. Barnes PJ. Airway pharmacology. In: Murray JF, Nadel JA, editors(s). Textbook of Respiratory Medicine. 3rd edition. Philadelphia: WB Saunders, 2000:267-96.
Bayoumi 1997
    1. Bayoumi RA. Does the mechanism of protection from falciparum malaria by red cell genetic disorders involve a switch to a balanced TH1/TH2 cytokine production mode? Medical Hypotheses 1997;48(1):11-7. - PubMed
Castro 1994
    1. Castro O, Brambilla DJ, Thorington B, Reindorf CA, Scott RB, Gillette P, et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood 1994;84(2):643-9. - PubMed
Corso 2005
    1. Corso M, Ravindranath TM. Albuterol-induced myocardial ischemia in sickle cell anemia after hemolysis from ceftriaxone administration. Pediatric Emergency Care 2005;21(2):99-101. - PubMed
Deeks 2021
    1. Deeks JJ, Higgins JP, Altman DG, editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.
Elbourne 2002
    1. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9. - PubMed
Gill 1995
    1. Gill FM, Sleeper LA, Weiner SJ, Brown AK, Bellevue R, Grover R, et al. Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. Blood 1995;86(2):776-83. - PubMed
Gray 1991
    1. Gray A, Anionwu EN, Davies SC, Brozovic M. Patterns of mortality in sickle cell disease in the United Kingdom. Journal of Clinical Pathology 1991;44(6):459-63. - PMC - PubMed
Handelsman 1991
    1. Handelsman E, Voulalas D. Albuterol inhalations in acute chest syndrome [letter]. American Journal of Diseases of Children 1991;145(6):603-4. - PubMed
Higgins 2017
    1. Higgins JP, Altman DG, Sterne JA, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from training.cochrane.org/handbook.
Higgins 2021
    1. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.
Knight 1999
    1. Knight J, Murphy TM, Browning I. The lung in sickle cell disease. Pediatric Pulmonology 1999;28(3):205-16. - PubMed
Knight‐Madden 2005
    1. Knight-Madden JM, Forrester TS, Lewis NA, Greenough A. Asthma in children with sickle cell disease and its association with acute chest syndrome. Thorax 2005;60(3):206-10. - PMC - PubMed
Koumbourlis 2001
    1. Koumbourlis AC, Zar HJ, Hurlet-Jensen A, Goldberg MR. Prevalence and reversibility of lower airway obstruction in children with sickle cell disease. Journal of Pediatrics 2001;138(2):188-92. - PubMed
Leong 1997
    1. Leong MA, Dampier C, Varlotta L, Allen JL. Airway hyperreactivity in children with sickle cell disease. Journal of Pediatrics 1997;131(2):278-83. - PubMed
Perin 1983
    1. Perin RJ, McGeady SJ, Travis SF, Mansmann HC Jr. Sickle cell disease and bronchial asthma. Annals of Allergy 1983;50(5):320-2. - PubMed
Platt 1994
    1. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. New England Journal of Medicine 1994;330(23):1639-44. - PubMed
Review Manager 2020 [Computer program]
    1. Review Manager 5 (RevMan 5). Version 5.4. The Cochrane Collaboration, 2020. Available at revman.cochrane.org.
Savoy 1988
    1. Savoy LB, Lim JD, Sarnaik SA, Jones DC. Prevalence of atopy in a sickle-cell anemia population. Annals of Allergy 1988;61(2):129-32. - PubMed
Schünemann 2021
    1. Schünemann HJ, Higgins JP, Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.
Sofowora 1970
    1. Sofowora EO. Bronchial asthma in the tropics. A study of 250 Nigerian patients. East African Medical Journal 1970;47(8):434-9. - PubMed
Thomas 1982
    1. Thomas AN, Pattison C, Serjeant GR. Causes of death in sickle-cell disease in Jamaica. British Medical Journal (Clinical Research Edition) 1982;285(6342):633-5. - PMC - PubMed
Vichinsky 2000
    1. Vichinsky EP, Neumayr LD, Earles AN, Williams R, Lennette ET, Dean D, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. New England Journal of Medicine 2000;342(25):1855-65. - PubMed
Weatherall 2001
    1. Weatherall DJ, Clegg JB. Inherited haemoglobin disorders: an increasing global health problem. Bulletin of the World Health Organization 2001;79(8):704-12. - PMC - PubMed
WHO 1993
    1. World Health Organization. Joint WHO/TIF Meeting on the Control of Haemoglobinopathies. Report of the 7th meeting of the WHO Working Group on the Control of Hereditary Anaemias, Nicosia, Cyprus; April 1993. Available at apps.who.int/iris/handle/10665/62495.
Wierenga 2001
    1. Wierenga KJ, Hambleton IR, Lewis NA. Survival estimates for patients with homozygous sickle-cell disease in Jamaica: a clinic-based population study. Lancet 2001;357(9257):680-3. - PubMed

References to other published versions of this review

Knight‐Madden 2003
    1. Knight-Madden JM, Hambleton IR. Inhaled bronchodilators for acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews 2003, Issue 3. Art. No: CD003733. [DOI: 10.1002/14651858.CD003733] - DOI - PubMed
Knight‐Madden 2012
    1. Knight-Madden JM, Hambleton IR. Inhaled bronchodilators for acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews 2012, Issue 7. Art. No: CD003733. [DOI: 10.1002/14651858.CD003733.pub2] - DOI - PubMed
Knight‐Madden 2014
    1. Knight-Madden JM, Hambleton IR. Inhaled bronchodilators for acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews 2014, Issue 8. Art. No: CD003733. [DOI: 10.1002/14651858.CD003733.pub3] - DOI - PubMed
Knight‐Madden 2016
    1. Knight-Madden JM, Hambleton IR. Inhaled bronchodilators for acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews 2016, Issue 9. Art. No: CD003733. [DOI: 10.1002/14651858.CD003733.pub4] - DOI - PMC - PubMed

Publication types

Substances